Clinical Trial Update: A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC [Phase 3]

View source ↗

Summary

A Phase III randomized trial assessed adding conventional transarterial chemoembolization (cTACE) to sorafenib versus sorafenib alone in advanced hepatocellular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Conventional transarterial chemoembolization (cTACE)
• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Advanced Adult Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED